 Run-in Arm to establish the safety and tolerability of BGB324 administered as a single agent. BGB324 will be administered at a loading dose of 600 mg on Day 1 and Day 2 of Cycle 1, followed by 200 mg daily thereafter. After 6 patients have been dosed and safety established Arm A dose escalation arm will be opened to confirm the BGB324 to be used in combination with erlotinib. 